The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung. The morphology of the original tumor was not characteristic of SCLC. The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase. It does not have detectable levels of L-DOPA decarboxylase or bombesin. The cells produce an abnormally sized p53 mRNA (3.7 Kb). C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells. The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern. The cells stain positively for neurofilaments and vimentin. There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs. NCI-H82 细胞系由 A.F. Gazdar 及其同事于 1978 年从一名患有小细胞肺癌的患者的胸膜液中提取。原始肿瘤的形态不是 SCLC 的特征。该品系是 SCLC 的生化和形态变体,表达神经元特异性烯醇化酶和肌酸激酶的脑同工酶。它没有可检测到的 L-DOPA 脱羧酶或铃蟾肽水平。细胞产生异常大小的 p53 mRNA (3.7 Kb)。 C-myc DNA 序列扩增约 25 倍,与正常细胞相比,c-myc RNA 增加了 24 倍。据报道,这些细胞表达功能性 ANP 受体,但用 ANP 处理不会改变它们的生长模式。细胞对神经丝和波形蛋白呈阳性染色。存在v-fes、v-fms、Ha-ras、Ki-ras、N-ras和c-raf 1 mRNA的表达。
Growth Properties
Epithelial
Recommended Medium And Supplement
RPMI 1640 medium supplemented with 4.5g/L glucose, 2mM L-glutamine, and 10% fetal bovine serum